STOCK TITAN

Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting. The shares were sold at a weighted average price of $11.25, within a range from $11.25 to $11.28, leaving 148,175 shares directly owned.

Positive

  • None.

Negative

  • None.
Insider Dulac Edward J III
Role EVP, Chief Financial Officer
Sold 8,111 shs ($91K)
Type Security Shares Price Value
Sale Common Stock F1, F2 8,111 $11.25 $91K
Holdings After Transaction: Common Stock — 148,175 shares (Direct)
Footnotes (2)
  1. F1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.
Shares sold 8,111 shares Mandatory sell-to-cover transaction on July 22, 2026 to satisfy tax withholding from RSU vesting
Weighted average sale price $11.25 per share Weighted average price for 8,111 shares sold in multiple transactions
Sale price range $11.25 to $11.28 Range of prices at which the 8,111 shares were sold on July 22, 2026
Shares owned after transaction 148,175 shares Directly owned common stock following the July 22, 2026 sell-to-cover transaction
sell-to-cover financial
"Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying tax"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSUs financial
"tax withholding obligation upon the vesting of RSUs on July 22, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did NTLA’s CFO report on July 22, 2026?

EVP and CFO Edward J. Dulac III reported a sale of 8,111 shares of Intellia Therapeutics common stock on July 22, 2026. This was a mandatory sell-to-cover transaction to satisfy tax withholding from RSU vesting, not a discretionary trade.

Was the NTLA CFO’s July 22, 2026 stock sale a discretionary trade?

No. The filing states the sale was a mandatory “sell-to-cover” to meet tax withholding obligations from RSU vesting. It explicitly notes this sale “does not represent a volitional trade” by the reporting person, distinguishing it from elective open-market selling.

How many NTLA shares did the CFO sell and at what price?

The CFO sold 8,111 shares of Intellia Therapeutics common stock at a weighted average price of $11.25 per share. Footnotes explain the shares were sold in multiple trades at prices ranging from $11.25 to $11.28, inclusive, on July 22, 2026.

How many Intellia Therapeutics (NTLA) shares does the CFO hold after the sale?

Following the sell-to-cover transaction, the CFO directly owns 148,175 shares of Intellia Therapeutics common stock. This reported figure in the filing reflects his direct holdings immediately after the July 22, 2026 transaction for tax withholding purposes.

What does “sell-to-cover” mean in the NTLA CFO’s Form 4?

In this context, “sell-to-cover” means the company sold 8,111 shares on the CFO’s behalf to cover tax withholding from vested RSUs. The footnote clarifies this transaction was mandatory for taxes and not a voluntary investment decision by the CFO.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dulac Edward J III

(Last)(First)(Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/22/2026S(1)8,111D$11.25(2)148,175D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.
James Basta, attorney-in-fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)